This Week in Cardiology

The SPRINT hypertension trial announcement, ABIM concessions, frailty as a predictor of PCI outcomes, and high interval training as therapy in type 2 diabetes are discussed in this week's podcast.

Ablating the left atrial appendage, the female athletic heart, pricy PCSK9 drugs, a sugar tax, and the potential of good nutrition are the topics discussed by Dr John Mandrola in this week's podcast.

Dr John Mandrola discusses studies from ESC, including CT-FFR, post-PCI bivalirudin, ezetimibe in diabetes, high-sensitivity troponin, resistant HTN, leadless pacing, and afternoon naps.

Two underused treatments for patients with CHF, mobile health apps, a potential breakthrough in obesity, and surgical AF ablation are discussed by Dr. John Mandrola.

Dr John Mandrola discusses cardiology's blind spot, exercise in the elderly, mental health as a risk factor for heart disease, and Southern "comfort" foods.

Early use of NOACs or warfarin, ICD generator change, obesity, social determinants of health, ABIM, and valsartan/sacubitril are the topics discussed by Dr John Mandrola.

Dr John Mandrola discusses rethinking the cath-lab reflex in patients with NSTE-ACS; good CPR, bad CPR; obesity; and racial differences in sudden cardiac death.

Topics reviewed by Dr Mandrola include statins and vulnerable plaque, seeing vulnerable plaque on CTA, the QT interval as a mortality predictor, trends in AF, and Malcolm Gladwell on US healthcare.

Apixaban in "valvular" AF, comorbidity burden in CHF, the value of targeting PVCs, and the population benefits of statins are the topics reviewed this week by Dr John Mandrola.

Dr John Mandrola reviews the FDA's decision to approve valsartan/sacubitril for CHF, statins and aggression, and the huge cardiovascular health costs of sugary beverages.